− Expanded oncology portfolio includes comprehensive prostate cancer franchise to address patient management across the care continuum −
– Agreement builds on Blue Earth Diagnostics’ established leadership position in rapid development and commercialization of PET radiopharmaceuticals –
– Theranostic rhPSMA radiopharmaceuticals have potential utility in both diagnostic imaging and therapy of prostate cancer
San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced that it has signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in radiopharmaceuticals and radiopharmaceutical technologies, and the Technical University of Munich (TUM). Under terms of the agreement, Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer. Blue Earth previously acquired exclusive rights to rhPSMA imaging technology in 2018 and now has two investigational Phase 3 clinical trials underway to investigate the use of lead candidate 18F-rhPSMA-7.3 for PET imaging in prostate cancer (“LIGHTHOUSE,” NCT04186819 and “SPOTLIGHT,” NCT04186845).